What are your research interests?
I am investigating new therapeutic approaches for trauma-associated haemorrhagic shock (severe blood loss); focusing particularly on the organ injury and dysfunction arising from ischaemia-reperfusion.
How did you first get involved with SCI?
I first got involved after presenting a poster in the Biological and Biomedical Sciences category at STEM for Britain 2021 where SCI was one of the sponsors of the event.
I would highly encourage my peers to join not only so they can be a part of a global multi-disciplinary community but also to benefit from the extensive career development and networking opportunities.
What do you hope to gain from your involvement with SCI?
As an ambassador, I hope to build on my communication, leadership and teamwork skills alongside like-minded individuals. More generally as a SCI member, I want to make the most out of the networking opportunities and find out more about the transition from academia to industry. I would also like to boost my personal and professional development through the mentoring programme which is a great chance to learn from someone who may have been in a similar position to you. Lastly, I look forward to attending events organised by SCI and reading the latest updates in the C&I Magazine.
SCI aims to be ‘where science meets business’. What is the potential commercial application of your research?
If I can identify biomarkers which can predict patient outcomes, detection assays could be created and used as point of care testing in hospitals. This would then allow better patient management and a more personalised treatment approach, if clinicians can foresee which patients may have a worse prognosis and require extra care/monitoring/intervention.
Nikita Patel
The William Harvey Research Institute, Queen Mary University of London, Translational Medicine & Therapeutics
External Links